Compare WVE & VRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WVE | VRTS |
|---|---|---|
| Founded | 2012 | 1988 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2015 | 1995 |
| Metric | WVE | VRTS |
|---|---|---|
| Price | $5.18 | $168.87 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 4 |
| Target Price | $29.81 | ★ $158.00 |
| AVG Volume (30 Days) | ★ 2.2M | 120.5K |
| Earning Date | 04-28-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 6.68% |
| EPS Growth | N/A | ★ 18.24 |
| EPS | N/A | ★ 7.72 |
| Revenue | ★ $3,704,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $85.67 | $1.66 |
| P/E Ratio | ★ N/A | $21.53 |
| Revenue Growth | ★ 149.43 | N/A |
| 52 Week Low | $5.02 | $121.61 |
| 52 Week High | $21.73 | $203.61 |
| Indicator | WVE | VRTS |
|---|---|---|
| Relative Strength Index (RSI) | 45.18 | 58.81 |
| Support Level | $5.46 | $160.83 |
| Resistance Level | $6.30 | $171.02 |
| Average True Range (ATR) | 0.28 | 5.66 |
| MACD | 0.03 | -0.59 |
| Stochastic Oscillator | 38.10 | 81.86 |
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Virtus Investment Partners Inc provides investment management and related services to institutions and individuals. It uses a multi-manager, multi-style approach, offering investment strategies from investment managers, each having its distinct investment style, autonomous investment process, and individual brand, as well as from select unaffiliated managers for certain funds. Through its multi-manager model, the group provides investment managers with distribution, business, and operational support. The Company operates in one business segment, namely as an asset manager providing investment management and related services for individual and institutional clients.